贯日翻译样本转分子医学研究中心（英译中）

Lily

The Center for Translational Molecular Medicine (CTMM)

转分子医学研究中心（CTMM）

Peter R. Luijten, Ph.D.

Peter R. Luijten博士

Cancer as well as cardiovascular, neurodegenerative, infectious and autoimmune diseases impose a heavy burden on mankind. The Center for Translational Molecular Medicine (CTMM) strives to significantly reduce the impact of these diseases and improve the quality of life for those who must live with them.

CTMM is dedicated to the development of Molecular Diagnostics and Molecular Imaging technologies, focusing firmly on the translational aspects of molecular medicine so that scientific results can be applied as quickly as possible in actual patient care. Achieving this objective could enable earlier and more precise diagnosis of disease and the design of highly personalized therapies.

癌症以及心血管疾病、神经退化疾病、感染性疾病、自体免疫性疾病给人类带来了巨大负担。转分子医学研究中心致力于大幅度减弱这些疾病所带来的影响，帮助那些无法根治的患者提高生活质量。转分子医学研究中致力于研究分子诊断与分子成像技术，紧紧关注分子药物的转译特性，以便能够尽快将科研成果应用于临床。这一目标的实现将辅助人们开展更早更精确的诊断，设计更加因人而治的疗法。

All Dutch university medical centers, several universities and more than 90 companies are involved, actively cooperating with one another to bring new products faster to the patient’s bedside. Currently, 25 CTMM research projects are active, involving a total of 125 partners and a research budget of 302.7 M€. Duration of the projects is 4 – 5 years, ending in 2015. Primary funding is provided by the Dutch government (50%), industry (25%) and academia (25%), with additional funding contributed by CTMM supporting foundations (Dutch Diabetes Foundation, Dutch Kidney Foundation, Dutch Arthritis Foundation, Dutch Cancer Society, Dutch Digestive Foundation and the Dutch Heart Foundation).

所有荷兰大学的医疗中心，多家大学及90多家公司积极参与了本研究中心的合作，为病人创造新药加快速度。目前，有25个CTMM研究项目正在进行，涉及125个合作方，研究预算达3.027亿欧元。项目耗时一般为4至5年，将于2015年结束。荷兰政府（50%）、工业界（25%）与学术界（25%）为本项目提供了主要资金。其他资金由多家CTMM的支持性基金会提供（包括荷兰糖尿病基金会、荷兰肾脏基金会、荷兰关节炎基金会、荷兰癌症基金会、荷兰消化基金会与荷兰心脏基金会）。

Peter R. Luijten received his training in physical and theoretical chemistry from 1972-1979 (Amsterdam). After finalizing his thesis on NMR studies of molecular dynamics in liquid crystals (1984, Amsterdam, San Diego), he became a research scientists at Philips Medical Systems in the Magnetic Resonance Imaging division. He developed multiple new technologies resulting in several patent applications and peer reviewed scientific journals. In 2005 he was appointed Professor of Functional Medical Imaging at the University Medical Center in Utrecht and chair of the imaging department of the UMC Utrecht in 2014. In 2007 he was appointed Chief Scientific Officer of the Center for Translational Molecular Medicine, a position he holds jointly with his academic appointment at the University of Utrecht.

Peter R. Luijten于1972年至1979年期间在阿姆斯特丹接受物理学与理论化学的教育。在结束他的液晶分子动力学核磁共振研究论文后（1984年，阿姆斯特丹、圣地亚哥），他成为了飞利浦医疗系统磁共振成像系的研究科学家。他开发了多种新技术，拥有多项专利申请，并与其他同行互评科技杂志。2005年，他被乌特勒支大学医疗中心授予为功能性医疗成像教授，并于2014年成为大学成像系主任。2007年，他被转分子医学研究中心任命为首席科学家，此职位与乌特勒支大学的学术职位紧密结合。

He served on the board of trustees of the International Society of Magnetic Resonance in Medicine, was appointed a fellow of this society in 1995 and received the European Magnetic Resonance Award for Basic Sciences in 2002.

Peter R. Luijten曾是国际社会核磁共振医学应用机构（International Society of Magnetic Resonance in Medicine）受托委员会委员，1995年被任命为该机构资深会员，2002年荣获欧洲基础科学核磁共振奖。

Paul Parren

SVP & Scientific Director

高级副总裁兼科学总监

Genmab is a publicly traded, international biotechnology company specializing in the creation and development of differentiated human antibody therapeutics for the treatment of cancer.  Founded in 1999, the company currently has one marketed antibody, Arzerra® (ofatumumab) for the treatment of certain chronic lymphocytic leukemia indications, a clinical pipeline with both late and early stage programs, and an innovative pre-clinical pipeline.  Genmab's technology base consists of validated and proprietary next generation antibody technologies - the DuoBody® platform for generation of bispecific antibodies, and the HexaBody™ platform which creates effector function enhanced antibodies. Genmab's deep antibody expertise is expected to provide a stream of future product candidates.  Partnering of selected innovative product candidates and technologies is a key focus of Genmab’s strategy and the company has alliances with top tier pharmaceutical and biotechnology companies.

Genmab公司是一家国际性上市生物技术公司，主营创造以及开发分化人体抗体疗法，达到治疗癌症的目的。成立于1999年，目前公司已经实现了一种抗体的市场化，即Arzerra®，用于治疗某种慢性淋巴白血病适应症，已经研制出一种早晚期治疗皆可使用的临床流水线，以及一种创新型临床前期流水线。Genmab公司的技术基础建立在多项已通过验证的下一代抗体专有技术基础之上，包括用于生成双特异性抗体的DuoBody®平台以及用于生成效应物功能强化抗体的HexaBody™平台。Genmab的资深抗体专业知识技术有望在未来研发出一系列新产品。精选的创新产品与技术的联合是Genmab公司运营的战略焦点。公司已经联合了多家顶尖制药及生物技术公司。

Dr. Paul Parren has been working in the field of recombinant antibodies for 25 years. He holds a PhD in molecular immunology from the University of Amsterdam (1992). Dr. Parren was an Associate Professor at The Scripps Research Institute in La Jolla, California, where he worked between 1993 and 2002 on studying the role of human antibodies in protection against viral infections. In 2002, he joined Genmab where he is a member of the senior management team. Dr. Parren serves in the position of Senior Vice President and Scientific Director and heads the Genmab Utrecht site. He leads an international group of about 120 employees responsible for Genmab’s Research and Pre-clinical development activities. Dr. Parren was appointed Professor of Translational Cancer Research at the Univ. Southern Denmark, Odense, Denmark in 2013.

Paul Parren博士已经在重组抗体领域工作了25年，并于1992年获得了阿姆斯特丹大学分析免疫学博士学位。1993年至2002年期间，Parren博士曾担任位于加利福尼亚拉霍亚的斯克里普斯研究所副教授一职，在那里，他对人类抗体是如何保护人体免受病毒感染的问题进行了研究。2002年，他加入Genmab公司，成为高级管理团队一员。Parren博士担任高级副总裁兼科技总监，领导Genmab公司在乌特勒支地区的发展。此外，他还领导一个拥有120名员工的国际团队负责Genmab公司的研究工作及临床前的发展活动。2013年，Parren博士被欧登塞南丹麦大学任命为癌症转译研究教授。

Bert Leufkens                             

Professor of Pharmacoepidemiology, head of the division of Pharmacoepidemiology & Clinical Pharmacology, Utrecht University

药物流行病学教授，乌特勒支大学药物流行病学与临床药理学系主任

Prof. Bert Leufkens obtained his PharmD and PhD degree from Utrecht University. During the mid-80s he worked at Leiden University and was a Fulbright Fellow at the University of Minnesota (US). In 1997 he was appointed as full professor of Pharmacoepidemiology at Utrecht University. From 2003-2005 was the Scientific Director of the Utrecht Institute for Pharmaceutical Sciences (UIPS). During 2006-2007 he was head of the Department of Pharmaceutical Sciences of the Faculty of Science in Utrecht. In 2007 he was appointed as Chair of Dutch Medicines Evaluation Board (MEB). Dr Leufkens is research and policy-wise active at several (inter)national platforms on pharmacoepidemiology (e.g. since 2009 co-opted member for pharmaco¬epidemiology of the EMA CHMP, past-President of ISPE), pharmacovigilance (past-member EMA Pharmacovigilance Working Party), orphan drugs (past-Chairman of the Dutch Steering Committee on Orphan Drugs), pharma policy (since 2008 Scientific Director of the Utrecht WHO Collaborating Centre for Pharmaceutical Policy and Regulation), regulatory science and scenario planning. He is (co) author of >400 papers in peer reviewed journals, book chapters and research reports.                                                                 

Bert Leufkens教授是乌特勒支大学医学博士与学术博士。上世纪八十年代中期，就职于荷兰莱顿大学，同时还是美国明尼苏达大学富布莱特奖学金资深会员；1997年被乌特勒支大学任命为药物流行病学全职教授；2003年至2005年期间，担任乌特勒支制药学研究所科学总监；2006至2007年期间，担任理学系药物学系主任；2007年，被荷兰药品评估委员会（MEB）任命为主席。Leufkens博士在多个药物流行病学(国际)国家性组织平台上，在研究与政策制定方面表现机智，活跃。这些国际组织所涉领域甚广，包括药物流行病学（如：自2009年起，被增选为欧洲药品管理局（EPA）及人用医药产品委员会（CHMP）委员，曾任国际制药工程协会（ISPE）总裁）、药物安全监测（曾是欧洲药品管理局（EPA）工作委员会成员）、罕用药（曾担任荷兰罕用药指导委员会主席）、制药政策（自2008年起，担任乌特勒支世界卫生组织合作中心制药政策与法规制定科学总监）、以及管理科学与情境规划。他在同行杂志评论上独立或合作发表了超过400篇论文、书稿及研究报告。

Johan Garssen

Professor Immunopharmacology of Nutrition and Head of Pharmacology, Utrecht University

Director Immunology Utrecht/Singapore, Nutricia Research Utrecht   

乌特勒支大学营养免疫药理学教授兼药理学系主任

乌特勒支免疫学研究所新加坡分所主任/纽迪希亚乌特勒支研究所主任

Prof. Johan Garssen studied medicine and biology at the Free University, Amsterdam. He specialised in immunology, pharmacology and biochemistry and finished both studies cum laude in 1987. He finished his PhD thesis at Utrecht University/Yale University in 1991 on the role of T cells in respiratory allergy, an immunopharmacological approach. After a postdoc period he became senior scientist at the National Institute of Public Health in the Netherlands. There he coached many research projects, both preclinical as well as clinical research, in the field of immunomodulation induced by a.o. nutritional ingredients, drugs and environmental agents. In 2002 he became head of the section immunology at Numico-Research and in October 2008 Director Immunology at Danone Research, currently Nutricia Research. Besides the above he is Professor Immunopharmacology at the Utrecht Institute for Pharmaceutical Sciences, Utrecht University, where in 2013 he was nominated University Profiling Professor Immunopharmacology. Johan Garssen published over 370 peer reviewed papers in the field of “immunomodulation”.

Gert Storm教授是乌特勒支大学一名（生物）制药科学家。自1991年9月始在乌特勒支大学任职；2000年，被授予教授称号（靶向给药）；1999年，曾担任兼职教授并于2009年被哥本哈根大学授予名誉教授。自2012年起，成为荷兰屯特大学MIRA研究所教授（靶向治疗学）。此外，他目前还在乌特勒支大学医疗中心就职，从事影像引导肿瘤干预措施工作。

Daan Crommelin                        

Emeritus professor of General Pharmaceutics, department of Pharmaceutical Sciences, Utrecht University

乌特勒支大学制药系综合制药学名誉教授

Prof. Daan Crommelin is emeritus-professor at the Department of Pharmaceutical Sciences at Utrecht University. Until December 2011 he was scientific director of the Dutch Top Institute Pharma (TI Pharma) in Leiden. He is adjunct professor at the Department of Pharmaceutics and Pharmaceutical Chemistry at the University of Utah. Crommelin is co-founder of OctoPlus, a Leiden based company specialized in the development of pharmaceutical (mainly protein based) product formulations and advanced drug delivery systems. He published extensively and is on the editorial board of 10 peer reviewed journals in the pharmaceutical sciences. He also advises venture capital groups. He chaired the Board of Pharmaceutical Sciences of the International Pharmaceutical Federation (F.I.P.), was chair of the organizing committee of the Pharmaceutical Sciences World Conference 2007 in Amsterdam. He is past president of the European Federation of Pharmaceutical Sciences (EUFEPS) and past vice-chair of the scientific advisory board of the European Innovative Medicines Initiative (IMI).

Daan Crommelin教授是乌特勒支大学制药系综合制药学名誉教授。2011年12月之前，他一直担任位于荷兰莱顿市的Top Institute Pharma科学总监一职。他曾担任美国犹他大学制药学与药物化学系兼职教授。Crommelin教授是OctoPlus公司创始人之一，这家公司座落于莱顿，主要开发药物（蛋白质为主）产品配方以及先进的药品输送体系。他的出版物甚多，是10家评论性杂志的编委。他还为风险投资集团献计献策。他还曾担任国际制药联合会（F.I.P）制药学董事会主席以及2007年阿姆斯特丹制药学世界会议组织委员会主席。此外，他还是欧洲制药学联盟（EUFEPS）前主席及欧洲创新药物倡议会科学咨询委员会前副主席。

Frank van Kuppeveld

Professor of Molecular Virology and Chairman of the Virology division of the Department of Infectious Diseases and Immunology of the Faculty of Veterinary Medicine, Utrecht University

乌特勒支大学分子病毒学教授，兼乌特勒支大学病毒学科感染性疾病以及兽医系免疫学系主任

Prof. Frank van Kuppeveld (1965), PhD, is the chairman of the Virology division of the Department of Infectious Diseases and Immunology of the Faculty of Veterinary Medicine. He obtained his PhD degree in Molecular Virology in 1997 at the Radboud University Medical Centre, Nijmegen, The Netherlands, where he was appointed assistant professor in 2001 and associate professor in 2008. He was awarded the Beijerinck Premium (award from the Royal Netherlands  Academy of Arts and Sciences for the most promising young virologist) in 2004 and he obtained prestigious personal grants from the Netherlands Organization of Scientific Research (NWO-VIDI in 2003, NWO-VICI in 2011). Furthermore, he set up EUVIRNA, a European training network on "+RNA viruses and antiviral drug development" (EC-FP7 Marie Curie Initial Training Network, 2011-2015), of which he is the coordinator. In 2012, he moved with his research group - which mainly focuses on enteroviruses (e.g. poliovirus, coxsackievirus, rhinovirus, enterovirus 71) - to Utrecht University where he was appointed as professor in molecular virology and chair of the Virology division. Besides enteroviruses and other picornaviruses, the research in the Virology division strongly focuses on the molecular biology (i.e. receptor usage, entry, replication, and spreading) and evolution of coronaviruses and influenza virus, with the aim to translate fundamental knowledge into new approaches for innovative vaccines and antiviral drugs.

Frank van Kuppeveld教授生于1965年，目前担任乌特勒支大学病毒学科感染性疾病以及兽医系免疫学系主任。1997年获得荷兰奈梅亨大学医学中心分子病毒学博士；2001年被任命为助理教授；2008年又被任命为副教授。2004年，获得贝杰林克奖金（由荷兰皇家艺术科学院颁发给最有前途的年轻病毒学家的奖金）以及由荷兰科学研究组织颁发的两次杰出个人助学金（2003年的NOW-VIDI助学金与2011年的NOW-VICI助学金）。此外，他还创建了EUVIRNA欧洲培训网络，培训内容为“+RNA病毒及抗病毒药物的开发”（EC-FP7玛丽·居里初始培训网络，2011至2015年）并负责协调工作。2012年，他随着他的研究团队（主要研究小儿麻痹症病毒、克沙奇病毒、鼻病毒、71号肠病毒之类的肠道病毒）一起转至乌特勒支大学。在该大学，他被任命为分子病毒学教授兼病毒科主任。除了肠道病毒及其他小核糖核酸病毒，病毒科的研究还主要集中在分子生物学（如：受体的使用、进入、复制及传播）以及冠状病毒及流感病毒的演化历程，他们希望能够运用所学到的基础知识寻找开发创新型疫苗及抗病毒药物的新途径。

Berend Jan Bosch                       

Assistant Professor, Department of Infectious Diseases and Immunology - Virology

病毒学　－　感染性疾病与免疫学助理教授

Dr. Berend Jan Bosch (1975) received his PhD degree in 2004 under supervision of prof. Peter Rotter at the Virology division of the Faculty of Veterinary Medicine, Utrecht University. Topic of his thesis was the assembly and fusion mechanism of the coronavirus spike glycoprotein. In 2005 he received the NWO-VENI grant and became assistant professor at the Virology division. He subsequently started his own research group working on the cell entry mechanism of membrane enveloped viruses, a complex and dynamic process mediated by viral glycoproteins which mediate cell surface attachment, endocytic uptake and membrane fusion. His work has led to the identification of several cell surface molecules to which viruses attach to initiate infection, such as dipeptidyl peptidase 4 and cellular glycosaminoglycan heparan sulphate for the zoonotic MERS coronavirus and RVFV bunyavirus, respectively. Moreover his group revealed the key role of host factors such as endosomal acidic pH and endo-lysosomal and extracellular proteases in the activation of viral glycoproteins for membrane fusion. His research on viral glycoproteins has translated in several vaccine development initiatives for bunya-, influenza- and coronavirus related diseases.

Berend Jan Bosch博士，1975年生，于2004年在乌特勒支兽医学院病毒科Peter Rotter教授的指导下获得博士学位。其博士论文课题为冠状病毒刺突蛋白的组配与融合机理。2005年，他获得NOW-VENI助学金，并开始担任病毒科助理教授一职，同时他还在陆续筹备组建自己的团队研究膜包病毒侵入细胞的机理，以及由病毒糖蛋白作为载体的一系列复杂的动态过程，这一过程承载着细胞表面附着物、细胞内吞吸收以及细胞膜的融合。他的工作导致多种细胞表面分子的鉴别，而病毒正是依靠这些分子进行初期的感染，如二肽基肽酶4和蜂窝糖胺聚糖硫酸乙酰肝素的人畜共患MERS冠状病毒和布尼亚病毒RVFV。此外，如内体的酸性pH值和内溶酶体及胞外蛋白酶在病毒糖蛋白对膜融合的活化。他在病毒糖蛋白的研究已经应用于多项免疫研发计划，用于治疗布尼亚病毒、流感病毒及冠状病毒引发的相关疾病。